These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24342895)

  • 1. Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia.
    De Francia S; DʼAvolio A; Ariaudo A; Pirro E; Piccione F; Simiele M; Fava C; Calcagno A; Di Perri G; Saglio G
    Ther Drug Monit; 2014 Jun; 36(3):410-2. PubMed ID: 24342895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia.
    Racil Z; Razga F; Klamova H; Voglova J; Belohlavkova P; Malaskova L; Potesil D; Muzik J; Zackova D; Polakova KM; Zdrahal Z; Malakova J; Suttnar J; Dyr J; Mayer J
    Hematol Oncol; 2014 Jun; 32(2):87-93. PubMed ID: 23963760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of imatinib targeted delivery in human leukocytes.
    Kralj E; Žakelj S; Trontelj J; Pajič T; Preložnik Zupan I; Černelč P; Ostanek B; Marc J; Kristl A
    Eur J Pharm Sci; 2013 Sep; 50(1):123-9. PubMed ID: 23643738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
    Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory.
    Bouchet S; Titier K; Moore N; Lassalle R; Ambrosino B; Poulette S; Schuld P; Belanger C; Mahon FX; Molimard M
    Fundam Clin Pharmacol; 2013 Dec; 27(6):690-7. PubMed ID: 23113675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on imatinib trough concentration, efficacy and their relation in chronic myelocytic leukemia].
    Zhong JS; Meng FY; Xu D; Zhou HS; Dai M
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):177-82. PubMed ID: 22781602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
    Teng JF; Mabasa VH; Ensom MH
    Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting.
    Faber E; Friedecký D; Mičová K; Rožmanová S; Divoká M; Jarošová M; Indrák K; Adam T
    Ann Hematol; 2012 Jun; 91(6):923-9. PubMed ID: 22231281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
    Gotta V; Widmer N; Decosterd LA; Chalandon Y; Heim D; Gregor M; Benz R; Leoncini-Franscini L; Baerlocher GM; Duchosal MA; Csajka C; Buclin T
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1307-19. PubMed ID: 25297989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.
    Gambacorti-Passerini C; Zucchetti M; Russo D; Frapolli R; Verga M; Bungaro S; Tornaghi L; Rossi F; Pioltelli P; Pogliani E; Alberti D; Corneo G; D'Incalci M
    Clin Cancer Res; 2003 Feb; 9(2):625-32. PubMed ID: 12576428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients.
    Streit F; Binder L; Hafke A; Brandhorst G; Braulke F; Haase D; Armbrust T; Cameron S; Ramadori G; Oellerich M; Walson P
    Ther Drug Monit; 2011 Oct; 33(5):632-43. PubMed ID: 21912334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Potential clinical benefit of therapeutic drug monitoring of imatinib in oncology].
    Turjap M; Juřica J; Demlová R
    Klin Onkol; 2015; 28(2):105-11. PubMed ID: 25882020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia.
    Mahon FX; Molimard M
    Leuk Res; 2009 Aug; 33(8):1147-8; author reply 1149-50. PubMed ID: 19395027
    [No Abstract]   [Full Text] [Related]  

  • 14. Utility of the trough plasma imatinib level monitoring at two time points in patients with the chronic myeloid leukemia-chronic phase.
    Sharma SK; Kumar S; Vijayakumar AR; Seth T; Mishra P; Mahapatra M; Sazawal S; Velpandian T; Saxena R
    J Cancer Res Ther; 2014; 10(2):305-8. PubMed ID: 25022382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.
    Pavlovsky C; Egorin MJ; Shah DD; Beumer JH; Rogel S; Pavlovsky S
    Pharmacotherapy; 2009 Sep; 29(9):1152-6. PubMed ID: 19698017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia.
    Boddy AV; Sludden J; Griffin MJ; Garner C; Kendrick J; Mistry P; Dutreix C; Newell DR; O'Brien SG
    Clin Cancer Res; 2007 Jul; 13(14):4164-9. PubMed ID: 17634544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum α1-acid glycoprotein, imatinib concentration and efficacy in chronic myeloid leukemia patients].
    Zhong JS; Meng FY; Xu D; Dai M; Wei YQ; Zhou HS
    Zhonghua Yi Xue Za Zhi; 2011 Aug; 91(30):2120-3. PubMed ID: 22093988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS.
    Iqbal Z; Elliott M; Watson DG; Holyoake T; Jørgensen H
    Pak J Pharm Sci; 2011 Jul; 24(3):285-91. PubMed ID: 21715261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monitoring of plasma concentration of imatinib mesylate in patients with chronic myeloid leukemia].
    Chen C; Wang W; Xu CG; Hou M; Wang LQ; Liu CF; Song Q; Ji CY
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):450-3. PubMed ID: 22213863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.